Gilead Sciences

Gilead Sciences Inc. casts itself as a biopharmaceutical company focused on the discovery, development, and commercialization of medicines for addressing various unmet medical needs. The company came into being as a brainchild of Michael L Riordan in 1987.

Headquartered in Foster California, the company specializes in the development of treatments for HIV Hepatitis B Hepatitis C and Influenza. Its lead products include Descovy and Truvada for the treatment of HIV infection and Harvoni for the treatment of liver diseases.

The company has grown through mergers and acquisitions. Its biggest acquisition to date is the purchase of Pharmasset inc. in a deal that cost it $10.4 billion. Its other notable acquisition is YM Biosciences for $510 million.

 Gilead Sciences Inc. went public in 1992 and got listed on the NASDAQ Stock Exchange in an Initial Public Offering that raised $86.25 million.

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.